Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
暂无分享,去创建一个
Y. Agid | L. Menalled | M. Murer | O. Gershanik | R. Raisman‐Vozari | G. Dziewczapolski | M. C. Garcia | Yves Agid | Gustavo Dziewczapolski | Liliana B. Menalled | Oscar Gershanik
[1] R. Wurtman,et al. Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse , 1981, Neurology.
[2] J. Thibault,et al. Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neurons. , 1991, Brain research. Developmental brain research.
[3] J. Langston,et al. Oxidation reactions in Parkinson's disease. Discussion , 1990 .
[4] E. Abercrombie,et al. Neurochemical Responses to 6‐Hydroxydopamine and L‐Dopa Therapy: Implications for Parkinson's Disease a , 1992, Annals of the New York Academy of Sciences.
[5] Mitsutoshi Yamamoto,et al. Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.
[6] D. Graham,et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.
[7] F. Hefti,et al. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.
[8] S. Fahn,et al. Considerations in the management of parkinsonism , 1978, Neurology.
[9] R. Clavier,et al. Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l‐DOPA and Carbidopa Chronically , 1984, Journal of neurochemistry.
[10] C. Goetz. Dopaminergic agonists in the treatment of Parkinson's disease , 1990, Neurologic clinics.
[11] Y. Agid,et al. Does levodopa aggravate Parkinson's disease? , 1988, Neurology.
[12] R. Edwards,et al. Differential expression of two vesicular monoamine transporters , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[13] M. Mena,et al. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid , 1993, Neuroreport.
[14] L. Grégoire,et al. Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[15] S. Miller,et al. Prolongation of the life-span in mice adapted to large amounts of L-dopa. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Clarke. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence , 1995, Movement disorders : official journal of the Movement Disorder Society.
[17] Anthony E. Lang,et al. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .
[18] R P Lesser,et al. Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.
[19] E. Hirsch,et al. Cellular Quantification of Tyrosine Hydroxylase in the Rat Brain by Immunoautoradiography , 1993, Journal of neurochemistry.
[20] Y. Agid,et al. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.
[21] E. Abercrombie,et al. Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats , 1990, Brain Research.
[22] D. Dexter,et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. , 1996, Free radical research.
[23] J. M. Ree,et al. Reinnervation after destruction of the dopaminergic system in the rat nucleus accumbens: a quantitative immunohistochemical analysis , 1996, Neuroscience Letters.
[24] Y Agid,et al. Mitochondrial Free Radical Signal in Ceramide‐Dependent Apoptosis: A Putative Mechanism for Neuronal Death in Parkinson's Disease , 1997, Journal of neurochemistry.
[25] L. Naudon,et al. Reserpine Affects Differentially the Density of the Vesicular Monoamine Transporter and Dihydrotetrabenazine Binding Sites , 1996, The European journal of neuroscience.
[26] Y. Agid,et al. Absence of neurotoxicity of chronic L‐DOPA in 6‐hydroxydopaminelesioned rats , 1997, Neuroreport.
[27] M. Yahr,et al. Autopsy findings in parkinsonism following treatment with levodopa , 1972, Neurology.
[28] Hoehn Mm,et al. Parkinson's disease: progression and mortality. , 1987 .
[29] J. Bennett,et al. L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? , 1994, Neuroreport.
[30] Y. Agid,et al. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.
[31] C. Marsden,et al. L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.
[32] D. Maraganore,et al. Levodopa therapy and survival in idiopathic Parkinson's disease , 1993, Neurology.
[33] D. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.
[34] Steven Moran,et al. Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat , 1995, Brain Research.
[35] R. Burke,et al. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[36] J. G. Nutt,et al. Long-duration response to levodopa , 1995, Neurology.
[37] E. Melamed. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. , 1986, Archives of neurology.
[38] J. Kurtzke,et al. Death rates from Parkinson's disease in Norway reflect increased survival , 1991, Neurology.
[39] J. Siegfried,et al. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. , 1976, European neurology.
[40] S. Fahn,et al. Selegiline and mortality in Parkinson's disease , 1996, Annals of neurology.
[41] C. Mytilineou,et al. Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.
[42] C. Waters,et al. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.
[43] M. Muenter,et al. Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.
[44] A. Björklund,et al. Brain-derived neurotrophic factor and neurotrophin- 4 5 modify neurotransmitter-related gene expression in the 6-hydroxydopamine-lesioned rat striatum , 1995, Neuroscience.
[45] A. Rajput,et al. Chronic low‐dose levodopa therapy in Parkinson's disease , 1984, Neurology.
[46] C. Marsden,et al. The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography , 1991, Neuroscience.
[47] C. Gall,et al. Expression of Neurotrophins by Midbrain Dopaminergic Neurons , 1993, Experimental Neurology.
[48] P. Ballard,et al. Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[49] A. Nieoullon,et al. Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat. , 1997, Brain research. Molecular brain research.
[50] I. Kanazawa,et al. Dopaminergic stimulation up‐regulates the in vivo expression of brain‐derived neurotrophic factor (BDNF) in the striatum , 1992, FEBS letters.
[51] A. Graybiel,et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.
[52] J. Townsend,et al. Pre- and Postsynaptic Neurotoxic Effects of Dopamine Demonstrated by Intrastriatal Injection , 1993, Experimental Neurology.
[53] E. Mufson,et al. Striatal Extracts from Patients with Parkinson's Disease Promote Dopamine Neuron Growth in Mesencephalic Cultures , 1993, Experimental Neurology.
[54] M. Yahr. LONG-TERM LEVODOPA IN PARKINSON'S DISEASE , 1977, The Lancet.
[55] B. McEwen,et al. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra , 1994, Brain Research.
[56] F. Mcdowell,et al. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. , 1975, Annals of internal medicine.
[57] P. Jenner,et al. Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine , 1993, Movement disorders : official journal of the Movement Disorder Society.
[58] S. Fahn,et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.
[59] J. Schneider. Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage , 1989, Pharmacology Biochemistry and Behavior.
[60] S. Fahn. Is levodopa toxic? , 1996, Neurology.
[61] F. Colpaert,et al. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease , 1991, Neuroscience.
[62] Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine , 1996, Neuroscience Letters.
[63] Y. Naum,et al. Growth of Pulmonary Alveolar Macrophages in vitro , 1973, Nature.
[64] S. Hirai,et al. Dopa and dopamine cause cultured neuronal death in the presence of iron , 1991, Journal of the Neurological Sciences.
[65] S. K. Han,et al. l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress , 1996, Journal of neurochemistry.
[66] S. Fahn,et al. Neurotoxicity of levodopa on catecholamine‐rich neurons , 1992, Movement disorders : official journal of the Movement Disorder Society.
[67] C. Joseph,et al. Levodopa in Parkinson disease: A long‐term appraisal of mortality , 1978, Annals of neurology.
[68] P. Rosenberg,et al. TOPA quinone, a kainate-like agonist and excitotoxin is generated by a catecholaminergic cell line , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[69] C. Goetz,et al. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures , 1991, Experimental Neurology.
[70] J. Olney,et al. Excitotoxicity of l-DOPA and 6-OH-DOPA: Implications for Parkinson's and Huntington's diseases , 1990, Experimental Neurology.
[71] M. Zigmond,et al. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[72] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[73] C. Sladek,et al. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons , 1990, Experimental Neurology.
[74] N. Quinn,et al. Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.
[75] M. Musicco,et al. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa , 1991, Neurology.
[76] R. Wurtman,et al. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.
[77] M. Martres,et al. A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride , 1987, Neuroscience.
[78] E. van der Velde,et al. Response fluctuations in Parkinson's disease , 1990, Neurology.
[79] D. Calne. The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.
[80] F. Mcdowell,et al. “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.
[81] J. Meerwaldt,et al. Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.
[82] M. Mena,et al. l‐DOPA Inhibits Complex IV of the Electron Transport Chain in Catecholamine‐Rich Human Neuroblastoma NB69 Cells , 1995, Journal of neurochemistry.
[83] J. Thibault,et al. Quantitative Autoradiography of Tyrosine Hydroxylase Immunoreactivity in the Rat Brain , 1991, Journal of neurochemistry.
[84] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[85] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.
[86] Y. Agid,et al. Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain , 1995, Journal of neurochemistry.